Posted: 11 September 2023
A new pathbreaking fund to drive the growth of Australia’s medtech and deeptech health ventures is now raising.
Launched this week at the 10-year celebration of the MedTech Actuator’s pathbreaking Origin program, Synthesis Capital is an ambitious venture fund designed to address the specific strengths and under-served potential of early-stage health innovation in Australia and across the Asia-Pacific region.
Targeting deep technology ventures in health, Synthesis will invest from pre-seed to series A+ – in Australia and the Asia-Pacific. Investments into the fund will be accepted from a range of corporate, individual, public and institutional partners.
Synthesis Capital aims to raise a fund size of $50 million or more, with the flexibility to scale up to $100 million. The target for the first close is set at $10-20 million, with plans for subsequent closings to meet investor demand.
Partnering with the MedTech Actuator, the fund will access a pipeline of talented, investment-ready startup teams primed for high growth and draw on a powerful ecosystem of venture development expertise. The initiative is partnered for impact with the Menzies Foundation, and gratefully recognises the Foundation’s support in its development to date.
The Synthesis Capital Fund will target an internal rate of return (IRR) of 25% net of all fees. Additionally, the fund will offer co-investment opportunities for limited partners (LPs).
The new fund is now actively raising and welcomes enquiries from potential LPs. For more visit Synthesis Capital www.synthesiscapital.vc
Synthesis Capital – key features:
- Health and deeptech focus – led by experts and leading players in health innovation
- Bridging the valleys of death and investing in the gap – from pre-seed to series A+ – in Australia and across the Asia-Pacific
- Exclusive partnership with the MedTech Actuator for deal flow and venture development
- Integration of capital and milestone-based investment scaling to actively manage venture risk
- Target fund size of $50m+, with a strategy capable of taking $100m+ (target first close $10-20m)
- Target IRR of 25%; co-investment opportunities for LPs
- Financial returns through relentless focus on health impact
